Mural Oncology (MURA) 2023年年度报告「NASDAQ」.pdf

《Mural Oncology (MURA) 2023年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Mural Oncology (MURA) 2023年年度报告「NASDAQ」.pdf（169页珍藏版）》请在三个皮匠报告上搜索。

1、 eUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,2023OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT O

2、F 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41837 Mural Oncology plc(Exact name of Registrant as specified in its Charter)Ireland98-1748617(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)10 Earlsfort TerraceDublin 2,D02 T380,Irel

3、andNot Applicable(Address of principal executive offices)(Zip Code)Registrants telephone number,including area code:+353-1-905-8020 Securities registered pursuant to Section 12(b)of the Act:Title of each class TradingSymbol(s)Name of each exchange on which registeredOrdinary shares,nominal value$0.0

4、1 per share MURA The Nasdaq Global MarketSecurities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the Registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.YES NO Indicate by check mark if the Registrant is not required to file reports

5、 pursuant to Section 13 or 15(d)of the Act.YES NO Indicate by check mark whether the Registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the Registrant was required to fil

6、e such reports),and(2)has been subject to such filing requirements for the past 90 days.YES NO Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the pre